株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

脳腫瘍 - 2024年までの疫学的予測

EpiCast Report: Brain Cancer - Epidemiology Forecast to 2024

発行 GlobalData 商品コード 347929
出版日 ページ情報 英文 42 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
脳腫瘍 - 2024年までの疫学的予測 EpiCast Report: Brain Cancer - Epidemiology Forecast to 2024
出版日: 2015年12月01日 ページ情報: 英文 42 Pages
概要

American Brain Tumor Associationによると、脳腫瘍には悪性、良性を含め120種類以上のものが存在します。世界7大市場で、脳腫瘍の診断済み発症件数は2014年の55,000件から年率1.3%で拡大し、2024年には62,000件になると予測されています。

レポートでは、脳腫瘍の概要とリスクファクター、世界7大市場における動向とともに、今後の疫学的予測をまとめています。

第1章 目次

第2章 イントロダクション

第3章 疫学

  • 疾患の背景
  • リスクファクターと併存疾患
  • 世界的動向
    • 7大市場の発症動向
    • 生存率動向
  • 予測方法
    • 用いた情報源
    • 用いなかった情報源
    • 予測方法と仮説
  • 疫学的予測:2013〜2023年
    • 診断済み発症件数
    • 年齢別診断済み発症件数
    • 性別診断済み発症件数
    • 年齢標準化診断済み発症件数
    • 5年間の診断済み罹患件数
    • タイプ別診断済み発症件数
  • 考察
    • 疫学的予測
    • 分析の限界
    • 分析の強み

第4章 付録

図表

目次
Product Code: GDHCER106-15

Primary brain cancer is defined as a malignant neoplasm that originates in the central nervous system (CNS), which consists of the brain and spinal cord, including the brain stem (NCI, 2015). The American Brain Tumor Association (ABTA) reports that there are over 120 different types of malignant and benign brain tumors, (ABTA, 2014). The type and severity of a brain tumor is defined by the cells from which the tumor originated, as well as by the proliferative potential of the abnormal growth, and only those tumors that are malignant are designated as cancer (NCI, 2015). Primary brain tumors are those that start in the brain and may, in time, migrate elsewhere in the body, while metastatic brain tumors are those that start elsewhere in the body and migrate to the brain or other parts of the CNS.

In the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan), GlobalData epidemiologists forecast that the diagnosed incident cases of brain cancer will increase from 55,084 cases in 2014 to 62,226 cases in 2024, at an Annual Growth Rate (AGR) of 1.30%. The US will have the highest number of diagnosed incident cases of brain cancer among the 7MM throughout the forecast period. The five-year diagnosed prevalent cases of brain cancer are also expected to increase from 84,704 cases in 2014 to 89,984 cases in 2024, at an AGR of 0.62%. The US will have the highest number of five-year diagnosed prevalent cases of brain cancer in 2014 and 2024, at 42,104 cases and 46,401 cases, respectively.

This report provides an overview of the risk factors, comorbidities, and the global and historical trends for brain cancer in the 7MM. It includes a 10-year epidemiological forecast for the diagnosed incident cases and the five-year diagnosed prevalent cases of brain cancer, each segmented by sex and age. Additionally, it includes a forecast for the diagnosed incident cases of brain cancer, segmented by type (glioblastoma, meningioma, ependymoma, oligodendroglioma, and CNS lymphoma). This forecast for brain cancer includes only primary malignant brain tumors originating in the CNS (ICD-10 codes C70-C72).

Scope

  • The brain cancer EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for brain cancer in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). This report includes a 10-year epidemiological forecast for the diagnosed incident cases and the five-year diagnosed prevalent cases of brain cancer, each segmented by sex and age. Additionally, it includes a forecast for the diagnosed incident cases of brain cancer, segmented by type (glioblastoma, meningioma, ependymoma, oligodendroglioma, and CNS lymphoma).
  • The brain cancer epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The brain cancer EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global brain cancer market.
  • Quantify patient populations in the global brain cancer market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for brain cancer therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. 7MM Incidence Trends
    • 3.3.2. 7MM Trends in Relative Survival
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast for Brain Cancer (2014-2024)
    • 3.5.1. Diagnosed Incident Cases of Brain Cancer
    • 3.5.2. Age-Specific Diagnosed Incidence of Brain Cancer
    • 3.5.3. Sex-Specific Diagnosed Incident Cases of Brain Cancer
    • 3.5.4. Age-Standardized Diagnosed Incidence of Brain Cancer
    • 3.5.5. Five-Year Diagnosed Prevalent Cases of Brain Cancer
    • 3.5.6. Diagnosed Incident Cases of Brain Cancer by Type
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Therapy Analysis and Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Description of Brain Cancer Types
  • Table 2: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of Brain Cancer
  • Table 3: 7MM, Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of Brain Cancer
  • Table 4: 7MM, Diagnosed Incident Cases of Brain Cancer, All Ages, Both Sexes, N, 2014-2024
  • Table 5: 7MM, Age-Specific Diagnosed Incident Cases of Brain Cancer, Both Sexes, N (Row %), 2014
  • Table 6: 7MM, Sex-Specific Diagnosed Incident Cases of Brain Cancer, All Ages, N (Row %), 2014
  • Table 7: 7MM, Five-Year Diagnosed Prevalent Cases of Brain Cancer, All Ages, Both Sexes, N, 2014-2024

List of Figures

  • Figure 1: 7MM, Age-Standardized Diagnosed Incidence Rate of Brain Cancer (Cases per 100,000 Population), All Ages, Men, 1998-2007
  • Figure 2: 7MM, Age-Standardized Diagnosed Incidence Rate of Brain Cancer (Cases per 100,000 Population), All Ages, Women, 1998-2007
  • Figure 3: 7MM, Diagnosed Incident Cases of Brain Cancer, All Ages, Both Sexes, N, 2014-2024
  • Figure 4: 7MM, Age-Specific Diagnosed Incident Cases of Brain Cancer, Both Sexes, N, 2014
  • Figure 5: 7MM, Sex-Specific Diagnosed Incident Cases of Brain Cancer, All Ages, N, 2014
  • Figure 6: 7MM, Age-Standardized Diagnosed Incidence of Brain Cancer, All Ages, N, 2014
  • Figure 7: 7MM, Five-Year Diagnosed Prevalent Cases of Brain Cancer, All Ages, Both Sexes, N, 2014-2024
  • Figure 8: 7MM, Diagnosed Incident Cases of Brain Cancer by Type, All Ages, Both Sexes, N, 2014
Back to Top